- $37.03m
- $31.02m
- $56.65m
U.S. RESEARCH ROUNDUP-Airbnb, Expedia Group, Parker-Hannifin
CVRx, Inc. reports results for the quarter ended June 30 - Earnings Summary
CVRx Q2 revenue beats estimates, outlook cut on sales force, payer challenges
Brief: CVRx Q2 Revenue USD 15.705 Million Vs. IBES Estimate USD 15.5 Million
CVRx, Inc. expected to post a loss of 52 cents a share - Earnings Preview
Brief: CVRx Announces Humana Medicare Advantage Coverage Policy For Barostim Therapy
CVRx's Q1 revenue rises 20%, beats expectations
Brief: CVRx Q1 Revenue USD 14.769 Million Vs. IBES Estimate USD 14.5 Million
CVRx preliminary Q1 revenue rises 20%, gross margin improves
CVRx Q4 revenue rises 4%, beats expectations
Brief: CVRx Q4 Revenue USD 16.024 Million Vs. IBES Estimate USD 15.8 Million
Brief: Cvrx Announces Initiation Of Benefit-Hf, A Landmark Heart Failure Trial
Brief: Cvrx Reports Preliminary Fourth Quarter And Fiscal Year 2025 Financial Results And Issues Fiscal 2026 Guidance
Brief: Cvrx Inc - On Jan 9, Amends Existing Loan And Security Agreement Dated Oct 31 2022 - SEC Filing
Brief: Cvrx Announces Implementation Of New Category I Cpt Codes For Barostim Therapy
Brief: CVRx May Offer And Sell Up To $150 Million In Securities - SEC Filing
U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Applovin Corp, Centuri Holdings
CVRx beats Q3 revenue expectations, gross margin climbs
Brief: CVRx Q3 Revenue USD 14.69 Million Vs. IBES Estimate USD 14.2 Million